What predicates have recent AI triage devices cited, and what testing did FDA expect?
- Mapping the question to product code QAS
- Reading 88 records under 21 CFR 892.2080
- Opening De Novo decision summary DEN170073
- Opening 510(k) summaries K261085, K260729 and K261317
- Extracting predicates and standalone performance
AI triage devices are cleared under product code QAS, a Class II device regulated at 21 CFR 892.2080 , with 88 510(k) records in openFDA . The category was created by De Novo DEN170073, Viz.ai’s ContaCT .
Recent submitters cite an earlier cleared triage device, not the De Novo. K261085, iSchemaview’s Rapid VO, cleared Jul 13, 2026 , flags suspected large vessel occlusion on adult head CTA and names the company’s own Rapid CTA 360, K251151 . K260729, GuideAI Health’s VAOT, cleared Jun 18, 2026 , names Aidoc’s BriefCase LVO Triage, K220709 , although VAOT flags occlusions in the aorta and the iliac, femoral and popliteal arteries . Aidoc’s own Special 510(k), K261317, also names K220709 .
FDA accepted standalone performance on a few hundred multi-site cases, reported as sensitivity and specificity with 95% confidence intervals, plus time to notification:
- K261085: 314 CTA cases from 33 clinical sites (99.0% US), 282 evaluable with 113 positive and 169 negative . Sensitivity 0.956 (95% CI 0.901–0.981), specificity 0.905 (95% CI 0.852–0.941), mean time to notification 3.2 to 3.3 minutes
- K260729: 317 cases from US sites, 165 positive and 152 negative . Sensitivity 0.915 (95% CI 0.862–0.953), specificity 0.901 (95% CI 0.842–0.944), time to notification under 5 minutes
In both, ground truth came from three board-certified radiologists by majority vote .